Ankang Beiyi Pharmaceutical Co., Ltd. was founded in 1996 and was officially established as a joint-stock company with the approval of the Shaanxi Provincial People's Government in 2005. It is a modern joint-stock high-tech pharmaceutical enterprise integrating standardized planting, scientific research, production and sales of medicinal materials. The company now has 218 employees, including 86 scientific research and technical personnel. It can independently complete all pre-clinical research work for various new drugs. There are 16 varieties that have been put into production, 3 varieties that have entered the Phase III clinical trial of new drugs, and the research and development of There are 12 products, many of which are domestic patented products, and their technical level is in the leading position in China.

The company has a registered capital of 65.36 million yuan, covers an area of ​​170 mu, a construction area of ​​58,660 square meters, and an investment of 576 million yuan on Chuangye East Road, Ankang High-tech Industrial Development Zone. In accordance with the national 2010 drug GMP specifications, traditional Chinese medicine raw materials and various Sixteen modern pharmaceutical GMP production lines including extracts, Chinese and Western medicine tablets, capsules, granules, pills, soft capsules, small infusions, small water needles, freeze-dried powder injections, and biological preparations. Annual production of 180 tons of total glycostem glycostoma (raw substances), puerarin, sorghum, matrine (raw substances for injection) and other Chinese medicine extracts, and annual production of 2 billion tablets, pellets, and packages of various Chinese patent medicines and Chinese and Western medicines. , , and bottle production capacity. The new factory built by the company was put into production and operation in 2014, and its annual sales revenue increased at a rate of 30%. It has now formed a sales network system that has spread to more than 30 provinces and cities in China.

In 2016, the company has started the research and development of traditional Chinese medicine formula granules and standardized planting of traditional Chinese medicine materials, and the work is progressing smoothly. At present, research and development and trial production, production technology, quality standards, fingerprint maps and other research work has been completed for more than 70 traditional Chinese medicine formula granules. The company is screening the varieties of authentic traditional Chinese medicinal materials in southern Shaanxi, signing a cooperation agreement on the development of traditional Chinese medicinal materials industry with the Pingli County Government, building more than 200 Chinese medicinal materials product sources of 9,000 mu, forming a model of government + company + base + poor households. , the standardized planting base of 100,000 mu is provided with standardized medicinal materials for the research and development and industrialization of traditional Chinese medicine formula granules.

The company built 600 mu of Gynostem Blue GAP seed source base in Pingli County and 30,000 mu of standardized planting base. In June 2005, it passed the national GAP certification for traditional Chinese medicinal materials. The Shaanxi Provincial Food and Drug Administration has submitted the request from Ankang Peking University to the pilot production enterprise of traditional Chinese medicine formula granules and submitted it to the State Food and Drug Administration, and entered the acceptance and filing procedures, creating great opportunities for accelerating the research and development and production of traditional Chinese medicine formula granules.